Inventiva S.A. has appointed Chris Benecchi as its new Chief Operating Officer, effective immediately. Benecchi, who previously served as CEO of Motric Bio, an Aditum Bio company, will lead the company's operational activities as it approaches the readout of its NATiV3 Phase 3 study of lanifibranor in MASH, expected in the last quarter of 2026, and prepares for potential commercialization. Inventiva's CEO, Andrew Obenshain, highlighted Benecchi's commercial, operational, and launch experience, noting his proven track record in bringing medicines to patients. With 30 years of biopharmaceutical leadership, Benecchi has held various commercial and operational roles, and holds an MBA from Duke University's Fuqua School of Business and a Bachelor of Arts from Colby College.
Takeda Pharmaceutical Co. Ltd.
Johnson & Johnson
Eli Lilly and CompanyInventiva S.AInventiva appointed Chris Benecchi as COO, adding commercial and launch experience ahead of the lanifibranor Phase 3 readout and potential commercialization.
Novo Nordisk A/S